--- title: "Roivant Sciences (ROIV): news, pipeline and catalysts" url: "https://aibio.space/companies/roivant-sciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Roivant Sciences news for investors: Roivant is a holding company that builds drug developers around individual programs, including Priovant, Immunovant…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Roivant has an approved drug and cash, but the trials that matter are still ahead Roivant now has an approved product and a large cash balance, but its value still depends on unfinished trials across several subsidiaries. The next six months bring several readouts, and the Moderna appeal could add up to $1.3 billion. This is a group of separate bets, and each one will be judged on its own data. Read the full desk view aibio.space Investor Rank · Opinion **6** /10 Neutral view An approved drug and a large cash balance, but revenue is minimal against heavy losses and value depends on unfinished trials across several subsidiaries. - **Technology**: 1/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Validated in one drug.** Brepocitinib won FDA approval in dermatomyositis; IMVT-1402 and mosliciguat have no efficacy data to match yet. - **Odds**: **Mixed so far.** Brepocitinib cleared phase 3 in dermatomyositis, while batoclimab missed in thyroid eye disease. Base rates give 57.8% from phase 3 to filing. - **Balance sheet**: **Well funded for now.** $3,842.1 million at June 30 before a $771.6 million Moderna receipt, against a quarterly net loss of $290.6 million. - **Main risk**: **Losses on thin revenue.** Revenue was $1.44 million and operating expenses $367.8 million in the June quarter. - **Watch next**: **Several readouts in 2H 2026.** Uveitis phase 3, mosliciguat phase 2 and IMVT-1402 cutaneous lupus data are all due. ## Top news on Roivant 1. 2026-08-06 Financings [Roivant posts $290.6M quarterly loss, $3.9B cash, and keeps buying back stock](https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/) The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end. 2. 2026-07-16 Distress [Arbutus expects to return up to approximately $230M to shareholders](https://aibio.space/news/arbutus-expects-return-up-approximately-230m-shareholders/) Arbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026. ## Dates **2H calendar 2026** Brepocitinib phase 3 topline data in non-infectious uveitis [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) **2H calendar 2026** Mosliciguat phase 2 topline data in PH-ILD; IMVT-1402 cutaneous lupus proof-of-concept data and difficult-to-treat rheumatoid arthritis update [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) **Calendar 2027** IMVT-1402 topline data in Graves' disease and myasthenia gravis [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) **No date given** Appeals court ruling on Section 1498 that decides the contingent $1.3 billion Moderna payment [Source](https://www.nasdaq.com/press-release/genevant-sciences-and-arbutus-biopharma-announce-225-billion-global-settlement) ## The money $3,842.1 million in cash, cash equivalents and marketable securities at June 30, 2026, before Genevant's $771.6 million share of Moderna's $950 million payment received July 8. The company's February 2026 release said its cash supports runway into profitability. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) $1.44 million for the quarter ended June 30, 2026, down from $2.17 million a year earlier. Net loss was $290.6 million. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) ## Risks on the record - Roivant expects to incur additional losses; net loss was $290.6 million in the June 2026 quarter. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) - Lisraya carries a boxed warning, and serious infections were 10% on the 30 mg dose against 1% on placebo in VALOR. [Source](https://www.pharmacytimes.com/view/fda-approves-first-oral-drug-for-dermatomyositis) - The $1.3 billion contingent Moderna payment depends on an appellate ruling on Section 1498. [Source](https://www.nasdaq.com/press-release/genevant-sciences-and-arbutus-biopharma-announce-225-billion-global-settlement) ## Questions investors ask ### What is aibio.space's Investor Rank for Roivant Sciences? 6 out of 10, our neutral view. An approved drug and a large cash balance, but revenue is minimal against heavy losses and value depends on unfinished trials across several subsidiaries. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What does Roivant Sciences do? Roivant is a holding company that creates subsidiaries, called Vants, around individual drug programs. They include Priovant (brepocitinib), Immunovant (IMVT-1402), Pulmovant (mosliciguat) and Genevant (lipid nanoparticle licensing). [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) ### Is Roivant's brepocitinib approved? Yes. The FDA approved brepocitinib as Lisraya for adults with dermatomyositis on Aug. 27, 2026. It is the first oral drug for the disease and carries a boxed warning for serious infections, death, cancer, cardiovascular events and thrombosis. [Source](https://www.pharmacytimes.com/view/fda-approves-first-oral-drug-for-dermatomyositis) ### How much cash does Roivant have? Roivant reported $3,842.1 million in cash, cash equivalents and marketable securities at June 30, 2026. That figure came before Genevant's $771.6 million share of Moderna's July payment. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) ### What is the Moderna settlement worth to Roivant? The settlement is worth up to $2.25 billion in total. Moderna paid $950 million in July, and Genevant's share was $771.6 million. Another $1.3 billion depends on an appeals court ruling on Section 1498. [Source](https://www.nasdaq.com/press-release/genevant-sciences-and-arbutus-biopharma-announce-225-billion-global-settlement) ### What are Roivant's next clinical catalysts? In the second half of 2026, Roivant expects brepocitinib phase 3 data in non-infectious uveitis, mosliciguat phase 2 data in PH-ILD, and IMVT-1402 cutaneous lupus data. IMVT-1402 Graves' disease and myasthenia gravis data are due in 2027. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) ### What is the latest Roivant Sciences (ROIV) stock news? Our latest story on Roivant Sciences, dated Aug 6, 2026: "Roivant posts $290.6M quarterly loss, $3.9B cash, and keeps buying back stock". The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end. [Source](https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/) ### What is Roivant Sciences's latest stock offering or financing news? Our latest financing story, dated Aug 6, 2026: "Roivant posts $290.6M quarterly loss, $3.9B cash, and keeps buying back stock". The holding company's June quarter showed higher research spending, almost no product revenue and a $950 million Moderna payment that arrived after quarter end. [Source](https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/) ### How much cash does Roivant Sciences have? From our story of Aug 6, 2026: The company reported consolidated cash and marketable securities of $3.9 billion, excluding a $950 million payment from Moderna that arrived in July. [Source](https://aibio.space/news/roivant-posts-290-6m-quarterly-loss-3-9b-cash-keeps-buying-back-stock/) ### What is Roivant Sciences's market cap? We do not publish live share prices. In its annual report, Roivant Sciences Ltd. put the market value of shares held by non-affiliates (public float) at $9.80 billion as of Sep 30, 2025. Source ### Is Roivant Sciences a smaller reporting company? SEC records list Roivant Sciences Ltd.'s filer category as: Large accelerated filer. Source ### Where is Roivant Sciences headquartered? SEC records list its business address as 7TH FLOOR, 50 BROADWAY, LONDON, SW1H 0DB. Source ### When does Roivant Sciences's fiscal year end? Roivant Sciences Ltd.'s fiscal year ends on March 31, per SEC records. Source ### What did Roivant Sciences last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-10-21. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_8k.htm) ### What industry is Roivant Sciences in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ## Legal and investor matters Checked against Roivant Sciences filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Part II, Item 1 of the 10-Q filed 2026-08-06 states that Roivant does not currently expect legal proceedings arising in the ordinary course of its business to have a material adverse effect on its business, operating results or financial condition. It covers that quarterly report only. [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) 1. 2026-08-06 Litigation Genevant and Arbutus patent suits against Pfizer and BioNTech continue Roivant's 10-Q filed August 6, 2026 says its subsidiary Genevant Sciences GmbH and Arbutus sued Pfizer and BioNTech in the U.S. District Court for the District of New Jersey in April 2023 over their COVID-19 vaccine. The court issued a claim construction ruling in September 2025. In July 2026 the two filed three more lawsuits, in Canada and before the Unified Patent Court. Roivant says it cannot predict timing or outcome. U.S. District Court for the District of New Jersey · Status: pending [Roivant Form 10-Q, 2026-08-06](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) 2. 2026-07-08 Litigation Moderna pays $950 million fixed amount under Genevant and Arbutus settlement Moderna paid Genevant Sciences GmbH and Arbutus $950 million on July 8, 2026, the fixed payment under the March 3, 2026 global settlement of patent litigation over lipid nanoparticle technology. Genevant received $771.6 million as its share. Moderna may owe up to $1.3 billion more, depending on the Federal Circuit's ruling on its 28 U.S.C. 1498 defense. Roivant says oral argument is expected in 2027. U.S. Court of Appeals for the Federal Circuit · Status: settled [Roivant Form 10-Q, 2026-08-06](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) 3. 2026-03-03 Litigation Genevant and Arbutus settle patent litigation with Moderna for up to $2.25 billion On March 3, 2026, Roivant subsidiary Genevant Sciences GmbH, Arbutus Biopharma and Moderna settled all pending U.S. and international patent suits over lipid nanoparticle technology in Moderna's vaccines. The U.S. case was filed in the District of Delaware in February 2022. Moderna consented to judgment of infringement and no invalidity of four patents and took a license. Payments total $950 million fixed plus up to $1.3 billion contingent. U.S. District Court for the District of Delaware · Status: settled [Roivant Form 8-K, 2026-03-03](https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/ef20067067_8k.htm) 4. 2025-06-24 Financing Roivant board authorizes additional $500 million share repurchase On June 24, 2025, the Roivant board authorized a common share repurchase program of up to $500 million, excluding fees and expenses. The 8-K says the authorization is in addition to the $1.5 billion program announced in April 2024, which had approximately $205 million of remaining capacity as of March 31, 2025 and has since been fully exhausted. [Roivant Form 8-K, 2025-06-25](https://www.sec.gov/Archives/edgar/data/1635088/000114036125023553/ef20051006_8k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Brepocitinib (Lisraya) | Dermatomyositis (adults) | FDA approved Aug. 27, 2026 (Priovant) [Source](https://www.pharmacytimes.com/view/fda-approves-first-oral-drug-for-dermatomyositis) | | Brepocitinib | Non-infectious uveitis | Phase 3 (CLARITY), topline expected 2H 2026 (Priovant) [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) | | Brepocitinib | Cutaneous sarcoidosis | Phase 3 (BEACON+) enrolling, topline expected 2028 (Priovant) [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) | | IMVT-1402 | Graves' disease | Potentially registrational trials, topline expected 2027 (Immunovant) [Source](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000100/0001764013-26-000100.pdf) | | Mosliciguat | Pulmonary hypertension with interstitial lung disease | Phase 2, topline expected 2H 2026 (Pulmovant) [Source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Roivant's uveitis win is clean on the primary endpoint, but the 'most effective' claim is a cross-trial call Roivant's filings and releases agree on the numbers, and it reported the batoclimab failures plainly. The gaps are in framing: the new uveitis release compares brepocitinib with other drugs' trials it did not run, and the cash runway message sits beside a 10-Q that says more capital may be needed. 1. Science · weight medium Uveitis results are strong, but "most effective" compares across trials **The company said:** "The magnitude and breadth of benefit observed across every ranked endpoint, compared with results reported in registrational trials of existing NIU therapies, suggest brepocitinib has the potential to be the most effective systemic, non-steroid treatment option for NIU" [source](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_ex99-1.htm) **The record says:** ClinicalTrials.gov lists CLARITY as randomized and quadruple-masked with 371 participants and a single primary outcome, "Time to treatment failure on or after Period 1 Week 6 up to Period 1 Week 48", matching the release. The release adds that the results came "despite a substantially more aggressive steroid taper than precedent NIU trials", and that 78.7% and 77.8% of placebo patients had treatment failure at Week 48. [source](https://clinicaltrials.gov/study/NCT06431373) **Our view:** The head-to-placebo result is solid: two identical trials, hazard ratios of 0.27 and 0.22. The comparison with other drugs is not head-to-head, and a faster steroid taper pushes placebo failure up, which widens the gap in any trial. Subgroup consistency is stated in the release without numbers. 2. Science · weight low Batoclimab failure reported plainly; the dosing explanation is post hoc **The company said:** "Immunovant's Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings" [source](https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/ef20069685_ex99-1.htm) **The record says:** The release says the studies "failed to meet their primary endpoint of ≥2mm proptosis responder rate at Week 24" and that patients "had greater levels of proptosis improvement from baseline after the initial 12-week high-dose period than after the following 12-week low-dose period, supporting the benefit of deeper IgG suppression." The 10-Q carries a $42.5 million accrual of non-cancelable costs tied to the discontinuation of batoclimab. [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) **Our view:** The failure is stated in the first bullet, which is the right way to do it. The deeper-suppression reading compares periods inside the same trials after the primary endpoint was missed, so it is a hypothesis. It matters because IMVT-1402, Immunovant's next FcRn drug, is being advanced on the same mechanism. 3. Press release vs filing · weight low Runway into profitability, beside a 10-Q that allows for more capital **The company said:** "Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $3.9 billion as of June 30, 2026, excluding the cash payment received from Moderna in July, supporting cash runway into profitability." [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) **The record says:** The 10-Q puts cash, cash equivalents and marketable securities at "approximately $3.8 billion" (the release adds restricted cash), net loss for the quarter at $290.6 million, and net cash used in operating activities at $270,504 thousand. It also says "Management expects to incur additional losses in the future to fund its operations and conduct product research and development and may require additional capital to fully implement its business plan." The filing contains no going-concern language. [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) **Our view:** The two documents are consistent: the same runway sentence appears in the 10-Q's business update. But the 10-Q's standard caution on additional capital is the more complete statement, and the $208.7 million of buybacks in the quarter use the same cash. 4. Press release vs filing · weight medium Moderna $950 million is not all Roivant's **The company said:** "Genevant and Arbutus received $950 million from Moderna in July 2026 under $2.25 billion settlement, with additional $1.3 billion contingent on favorable resolution of Moderna's § 1498 appeal" [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) **The record says:** The 10-Q says "Genevant received $771.6 million for its portion of the Fixed Payment" and that its parent "expects to distribute up to $188 million of the Fixed Payment to non-RSL common shareholders of GSL, including Arbutus, and holders of equity awards". Roivant held 83% of the parent as of June 30, 2026. The contingent payment depends on the Federal Circuit's § 1498 ruling, and under some outcomes Genevant and Arbutus must return it to Moderna with interest. [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) **Our view:** The release is accurate about who received the money. For an investor in Roivant, the relevant figure is the amount left after the up-to-$188 million distribution and $22.9 million of settlement bonuses the 10-Q accrues, and the $1.3 billion is a legal outcome, not cash in hand. 5. Legal and disclosure record · weight low No securities litigation disclosed; Roivant units are plaintiffs in patent suits **The record says:** Part II, Item 1 of the 10-Q says "We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition." Note 5 describes the March 3, 2026 settlement of Genevant and Arbutus patent suits against Moderna in the U.S. and internationally, in which "Moderna consented to entry of a judgment of infringement and of a judgment of no invalidity of four Genevant/Arbutus patents". The release adds new Genevant and Arbutus suits against Pfizer and BioNTech in Canada and before the Unified Patent Court. No securities litigation or enforcement disclosed in the latest filing. [source](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) **Our view:** Roivant's documented legal exposure is on the plaintiff side. The Pfizer and BioNTech cases are early, and the Moderna contingent payment is the one open item with a dollar figure attached. Documents we compared - [Roivant fiscal Q1 2026 results press release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/q1fy2026roivantearningsrel.htm) 2026-08-06 - [Roivant and Priovant CLARITY-1 and CLARITY-2 phase 3 release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_ex99-1.htm) 2026-10-21 - [Roivant brepocitinib LPP and batoclimab TED release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1635088/000114036126012885/ef20069685_ex99-1.htm) 2026-04-02 - [Roivant Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) 2026-08-06 - [ClinicalTrials.gov NCT06431373 (CLARITY)](https://clinicaltrials.gov/study/NCT06431373) 2026-01-12 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ROIV on TradingView](https://www.tradingview.com/symbols/NASDAQ-ROIV/). ## SEC filings and registration - **SEC name**: Roivant Sciences Ltd. - **CIK**: 1635088 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ROIV (Nasdaq) - **State or country of incorporation**: D0 - **Fiscal year ends**: March 31 - **Filer category**: Large accelerated filer - **Business address**: 7TH FLOOR, 50 BROADWAY, LONDON, SW1H 0DB - **Phone**: 441-295-5950 - **Shares outstanding**: 722,323,015 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126040332/ef20084121_8k.htm) filed 2026-10-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000095/roiv-20260916.htm) filed 2026-09-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126035859/ef20081686_8k.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034854/ef20081283_8k.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126034735/ef20081229_8k.htm) filed 2026-08-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000090/roiv-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1635088/000163508826000088/roiv-20260806.htm) filed 2026-08-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1635088/000114036126029955/ny20073886x1_def14a.htm) filed 2026-07-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001635088), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/roivant-sciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Roivant Sciences (ROIV): news, pipeline and catalysts", 2026-10-31, https://aibio.space/companies/roivant-sciences/